Moderna (MRNA)

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.